Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts

Transplantation
M S SabatineH Auchincloss

Abstract

Exogenous soluble tumor necrosis factor receptor (TNFR) has been shown to be an effective immunosuppressant. It has yet to be tested whether tissues secreting soluble TNFR, when transplanted into a foreign host, could locally generate immunosuppression and therefore manifest prolonged survival. A murine tumor line was transfected with the gene encoding a chimeric protein consisting of the extracellular domain of the human 75-kDa TNFR fused to the Fc region of the human IgG1 heavy chain. This tumor line was then injected into allogeneic recipients. Transfected tumor cells were shown to secrete soluble TNFR. When transplanted into minor histocompatibility antigen-disparate allogeneic recipients, these tumor cells grew as a solid tumor and resisted rejection, whereas untransfected tumors and interleukin-4 receptor transfectant controls were rejected within 4 weeks. The resistance to rejection could be reversed by coadministration of an anti-TNFR monoclonal antibody. Prolongation of graft survival can be achieved by genetically altering transplanted tissue to secrete soluble cytokine receptors.

References

Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A CarswellB Williamson
Jan 1, 1992·Immunologic Research·J RotheW Lesslauer
Jul 2, 1992·Nature·T Farrah, C A Smith
Apr 15, 1991·Biochemical and Biophysical Research Communications·C A SmithR G Goodwin
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N HaradaA Miyajima
Sep 1, 1989·Clinical Immunology and Immunopathology·R R GhobrialH Auchincloss
Nov 1, 1988·European Journal of Haematology·C PeetreI Olsson
Mar 16, 1989·Nature·E Y JonesN P Walker
Mar 1, 1989·European Journal of Haematology·I OlssonG Adolf
Jan 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·T CollinsJ S Pober
Jun 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·M P BevilacquaM A Gimbrone
Mar 1, 1986·The Journal of Experimental Medicine·P P Nawroth, D M Stern
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·W L FodorS P Squinto
Sep 10, 1993·Cell·L A TartagliaD V Goeddel
Jun 27, 1996·The New England Journal of Medicine·F Bazzoni, B Beutler
Oct 7, 1958·Annals of the New York Academy of Sciences·P A GORER
Oct 1, 1995·Trends in Cell Biology·P VandenabeeleW Fiers

❮ Previous
Next ❯

Citations

Feb 13, 2003·Journal of Biomedical Materials Research. Part a·Berit L StrandGudmund Skjåk-Braek

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.